前沿生物-U
(688221)
| 流通市值：45.14亿 | | | 总市值：45.14亿 |
| 流通股本：3.75亿 | | | 总股本：3.75亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 28,328,182.53 | 129,472,935.98 | 91,643,894.39 | 51,056,036.51 |
| 营业收入 | 28,328,182.53 | 129,472,935.98 | 91,643,894.39 | 51,056,036.51 |
| 二、营业总成本 | 74,909,155.77 | 405,686,029.6 | 282,018,728.06 | 185,196,329.54 |
| 营业成本 | 19,130,499.87 | 85,546,537.91 | 60,953,794.67 | 35,377,390.3 |
| 税金及附加 | 775,150.96 | 4,597,169.4 | 3,633,349.39 | 2,319,054.67 |
| 销售费用 | 21,243,275.06 | 86,344,001.84 | 47,921,544.66 | 34,124,281.19 |
| 管理费用 | 17,144,817.33 | 84,816,363.24 | 52,388,599.62 | 36,453,249.64 |
| 研发费用 | 16,803,233.38 | 137,205,648.06 | 109,341,964.29 | 72,701,164.58 |
| 财务费用 | -187,820.83 | 7,176,309.15 | 7,779,475.43 | 4,221,189.16 |
| 其中:利息费用 | 2,363,345.93 | 10,271,685.7 | 7,916,503.87 | 5,151,960.74 |
| 其中:利息收入 | 2,804,501.34 | 4,120,130.85 | 1,801,887.66 | 969,740.01 |
| 加:公允价值变动收益 | -206,446.41 | 83,505.51 | 991,376.04 | 849,425.97 |
| 加:投资收益 | 461,621.71 | 84,091,885.06 | 11,638,399.52 | 8,015,258.96 |
| 资产处置收益 | 15,353.93 | 18,798.64 | 18,798.64 | 18,798.64 |
| 资产减值损失(新) | -152,429.13 | -46,727,551.35 | -41,141,862.41 | -41,556,725.57 |
| 信用减值损失(新) | -897,500.57 | 253,226.64 | -1,470,354.38 | -77,112.91 |
| 其他收益 | 3,224,253.28 | 37,399,668.2 | 27,143,391.83 | 6,681,337.78 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -44,136,120.43 | -201,093,560.92 | -193,195,084.43 | -160,209,310.16 |
| 加:营业外收入 | 16,187.67 | 22,845.66 | 20,499.13 | 4,150.44 |
| 减:营业外支出 | 1,584.65 | 311,895.13 | 283,168.87 | 253,918.43 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -44,121,517.41 | -201,382,610.39 | -193,457,754.17 | -160,459,078.15 |
| 六、净利润 | -44,121,517.41 | -201,382,610.39 | -193,457,754.17 | -160,459,078.15 |
| 持续经营净利润 | -44,121,517.41 | -201,382,610.39 | -193,457,754.17 | -160,459,078.15 |
| 归属于母公司股东的净利润 | -44,121,517.41 | -201,382,610.39 | -193,457,754.17 | -160,459,078.15 |
| (一)基本每股收益 | -0.12 | -0.54 | -0.52 | -0.43 |
| (二)稀释每股收益 | -0.12 | -0.54 | -0.52 | -0.43 |
| 八、其他综合收益 | 21,559.46 | 11,919.84 | -9,917.82 | 4,068 |
| 归属于母公司股东的其他综合收益 | 21,559.46 | 11,919.84 | -9,917.82 | 4,068 |
| 九、综合收益总额 | -44,099,957.95 | -201,370,690.55 | -193,467,671.99 | -160,455,010.15 |
| 归属于母公司股东的综合收益总额 | -44,099,957.95 | -201,370,690.55 | -193,467,671.99 | -160,455,010.15 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-31 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |